Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Oxford vaccine to be available by April 2021 in India
  • India

    Oxford vaccine to be available by April 2021 in India

    Shalini Ojha
    Written by
    Shalini Ojha
    Twitter
    Last updated on Nov 20, 2020, 11:09 am
    Oxford vaccine to be available by April 2021 in India
  • Pune-based Serum Institute of India, which has partnered with Oxford University and British pharma giant AstraZeneca, plans to seek an emergency approval from the government of India next month, for providing the coronavirus vaccine to "corona warriors" and the elderly.

    The vaccine, dubbed "Covishield," has shown splendid results.

    By April 2021, the general public would get doses, SII CEO Adar Poonawalla said on Thursday.

  • In this article
    The vaccine produced strong response among older adults: Report SII is working on a "pandemic-level facility" General public will get it for Rs. 500-600 SII wants emergency use authorization to cater to select groups All depends on satisfactory results from UK Every Indian will be inoculated in two-three years Long-term efficacy of vaccine can't be judged now
  • Effectiveness

    The vaccine produced strong response among older adults: Report

    The vaccine produced strong response among older adults: Report
  • Yesterday, The Lancet medical journal published more details about the vaccine, revealing that doses generated a strong response among older adults. This assumes significance as the elderly are more susceptible to catching the contagion, and falling severely ill.

    For the study, 560 adults, 240 of whom were aged above 70, were considered.

    Separately, the results from late-stage trials are expected in the coming weeks.

  • Statement

    SII is working on a "pandemic-level facility"

    SII is working on a "pandemic-level facility"
  • For months now, the Oxford vaccine has induced hope among Indians. And Poonawalla is confident his company can step up to meet the demands.

    Speaking at HT Leadership Summit, he said SII is working on a "pandemic-level facility that can handle any pathogen or platform."

    He also said the Indian government will get the vaccine at a much cheaper price, because of the volumes.

  • Price

    General public will get it for Rs. 500-600

  • The vaccine could cost the government somewhere between Rs. 225 and Rs. 300 "because they will be buying large volumes," explained Poonawalla.

    "The general public, as I mentioned, will probably have to pay around Rs. 500-600," he said, underlining that it's cheaper than other vaccines.

    This means that the vaccine (as two doses would be needed) would cost nearly Rs. 1,000.

  • Plan

    SII wants emergency use authorization to cater to select groups

  • On SII's plan, Poonwalla said the company will approach Drug Controller General of India (DCGI) for emergency use approval after authorities abroad, like MHRA (Medicines and Healthcare products Regulatory Agency) and the European EMEA (European Medicines Agency), also give similar permission.

    "Again, that will be - just to clarify - a limited use for frontline workers and the elderly," he reiterated.

  • Quote

    All depends on satisfactory results from UK

  • "If we have a good UK result coming in end of November-early December, we apply for an emergency licensure use. So, you have the vaccine for - again - the vulnerable populations by Jan-Feb and then...March-April for the general public," he added.

  • Details

    Every Indian will be inoculated in two-three years

    Every Indian will be inoculated in two-three years
  • The CEO of SII also said that every Indian will be inoculated in about two-three years, explaining that not only supply constraints, but budget, logistics, and infrastructure would also dictate the process.

    "And then, people should be willing to take the vaccine. So these are the factors that lead up to being able to vaccinate 80-90% of the population," he added.

  • Safety

    Long-term efficacy of vaccine can't be judged now

  • When asked about efficiency, Poonawalla urged to keep patience. "The efficacy and immunogenicity results from the Indian trials will come out in about a month-and-a-half," he said.

    He stressed that the vaccine generated a good T-cell response.

    "Time will tell if these vaccines are going to protect you in the long term. Nobody can answer that for any of the vaccines today," he asserted.

  • Oxford University
  • HT Leadership Summit
  • Coronavirus
  • Serum Institute of India
  • Adar Poonawalla
  •  
Latest News
  • UK expands COVID-19 vaccine program to those over 45
    UK expands COVID-19 vaccine program to those over 45
    World
  • SSR death case: Two drug peddlers arrested by NCB
    SSR death case: Two drug peddlers arrested by NCB
    Entertainment
  • ICC Player of the Month Awards: Bhuvneshwar, Lizlee taste success
    ICC Player of the Month Awards: Bhuvneshwar, Lizlee taste success
    Sports
  • COVID-19: 52 inmates test positive at Delhi's Tihar jail
    COVID-19: 52 inmates test positive at Delhi's Tihar jail
    India
  • COVID-19 pandemic a long way from over, says WHO chief
    COVID-19 pandemic a long way from over, says WHO chief
    World
Related Timelines
  • SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    India
  • US: FDA grants emergency use approval for Moderna's COVID-19 vaccine
    US: FDA grants emergency use approval for Moderna's COVID-19 vaccine
    World
  • FDA advisors recommend Emergency Use Authorization of Moderna vaccine
    FDA advisors recommend Emergency Use Authorization of Moderna vaccine
    World
  • No emergency approval for SII, Bharat Biotech's vaccine candidates yet
    No emergency approval for SII, Bharat Biotech's vaccine candidates yet
    Science
Trending Topics
ISRO Vaccine
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Chris Lynn Samsung Virat Kohli
Rohit Sharma Cricket News Mahendra Singh Dhoni YouTube Hollywood News WhatsApp Bollywood News Real Madrid ISRO Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Apple Tesla
Royal Challengers Bangalore Toyota Fashion Tips Amit Shah Mercedes Sidharth Malhotra Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV
Smart TV Marvel Comics Avengers Neha Kakkar
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021